{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:49:49Z","timestamp":1789609789329,"version":"build-2803163510"},"reference-count":30,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To evaluate the association between semaglutide 2.4\u2009mg and major adverse cardiovascular events (MACE) among adults with clinical atherosclerotic cardiovascular disease (ASCVD) and overweight\/obesity without diabetes in real\u2010world clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>Adults aged \u2265\u200945\u2009years with overweight\/obesity and clinical ASCVD were identified from a United States database (2016\u20132024). Patients initiating semaglutide 2.4\u2009mg were matched 1:2 with individuals not treated with semaglutide 2.4\u2009mg through a propensity score model including &gt;\u200970 demographic and clinical covariates. Primary outcomes were revised 3\u2010point MACE (rMACE\u20103: myocardial infarction [MI], stroke, all\u2010cause mortality) and revised 5\u2010point MACE (rMACE\u20105: rMACE\u20103, heart failure [HF] hospitalisation, coronary revascularization). Secondary outcomes included 3\u2010point MACE and 5\u2010point MACE (replacing all\u2010cause mortality with cardiovascular\u2010related mortality) and HF composite outcomes; exploratory outcomes were incident type 2 diabetes (T2D), major adverse kidney events (MAKE) and major obesity\u2010related adverse events (MORAE). Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox proportional hazards models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The final sample comprised 38\u2009308 patients with semaglutide 2.4\u2009mg use propensity\u2010score matched to 76\u2009615 patients without. Over a mean follow\u2010up of 8.6\u2009months, semaglutide 2.4\u2009mg significantly reduced the risk of rMACE\u20103 (HR: 0.55; 95% CI: 0.47\u20130.65), rMACE\u20105 (0.63; 0.56\u20130.71), MACE\u20103 (0.66; 0.56\u20130.78) and MACE\u20105 (0.69; 0.62\u20130.77). Semaglutide 2.4\u2009mg also significantly reduced the risk of HF composite outcomes, T2D, MAKE and MORAE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Semaglutide 2.4\u2009mg was associated with a significantly reduced risk of MACE and other obesity\u2010related outcomes, extending prior evidence of benefits to a broader clinical ASCVD population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.70686","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T06:28:14Z","timestamp":1774592894000},"page":"4975-4990","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Lower Risk of Cardiovascular Events in Patients With Clinical Atherosclerotic Cardiovascular Disease Who Initiated Semaglutide 2.4\u2009mg in the Real\u2010World: Results From the SCORE\u2014Clinical\n                    <scp>ASCVD<\/scp>\n                    Study"],"prefix":"10.1111","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5745-1636","authenticated-orcid":false,"given":"Michael G.","family":"Nanna","sequence":"first","affiliation":[{"name":"Section of Cardiovascular Medicine, Department of Internal Medicine Yale School of Medicine  New Haven Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Mena\u2010Hurtado","sequence":"additional","affiliation":[{"name":"Section of Cardiovascular Medicine, Department of Internal Medicine Yale School of Medicine  New Haven Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Divino","sequence":"additional","affiliation":[{"name":"Novo Nordisk Inc.  Plainsboro New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenxiang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Novo Nordisk Inc.  Plainsboro New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5317-1909","authenticated-orcid":false,"given":"Yan","family":"Chen","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc.  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7858-979X","authenticated-orcid":false,"given":"Joanna","family":"Boland","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc.  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlin","family":"Song","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc.  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Traina","sequence":"additional","affiliation":[{"name":"Novo Nordisk Inc.  Plainsboro New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerem","family":"Ozer","sequence":"additional","affiliation":[{"name":"Novo Nordisk Inc.  Plainsboro New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip K.","family":"Knop","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S  Bagsv\u00e6rd Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim G.","family":"Smolderen","sequence":"additional","affiliation":[{"name":"Section of Cardiovascular Medicine, Department of Internal Medicine Yale School of Medicine  New Haven Connecticut USA"},{"name":"Section of Psychology, Department of Psychiatry Yale School of Medicine  New Haven Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2018.10.011"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000973"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2009.55"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30925-9"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/20503121241310013"},{"key":"e_1_2_10_7_1","volume-title":"Atherosclerosis","author":"Pahwa R.","year":"2023"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12872\u2010022\u201002601\u20100"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001168"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307563"},{"key":"e_1_2_10_11_1","unstructured":"Food and Drug Administration (FDA) \u201cFDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults With Obesity or Overweight \u201d(2025) https:\/\/www.fda.gov\/news\u2010events\/press\u2010announcements\/fda\u2010approves\u2010first\u2010treatment\u2010reduce\u2010risk\u2010serious\u2010heart\u2010problems\u2010specifically\u2010adults\u2010obesity\u2010or."},{"key":"e_1_2_10_12_1","unstructured":"Novo Nordisk \u201cWegovy Receives FDA Approval for Cardiovascular Risk Reduction in Adults With Known Heart Disease and Overweight or Obesity \u201d(2024) https:\/\/www.prnewswire.com\/news\u2010releases\/wegovy\u2010receives\u2010fda\u2010approval\u2010for\u2010cardiovascular\u2010risk\u2010reduction\u2010in\u2010adults\u2010with\u2010known\u2010heart\u2010disease\u2010and\u2010overweight\u2010or\u2010obesity\u2010302084454.html."},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70080"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.11.002"},{"key":"e_1_2_10_15_1","doi-asserted-by":"crossref","unstructured":"H. C.CousinsandR. B.Altman \u201cAssociation Between Spironolactone Use and COVID\u201019 Outcomes in Population\u2010Scale Claims Data: A Retrospective Cohort Study \u201d medRxiv(2023) https:\/\/doi.org\/10.1101\/2023.02.28.23286515.","DOI":"10.1101\/2023.02.28.23286515"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010024\u201058719\u2010y"},{"key":"e_1_2_10_17_1","unstructured":"Komodo Health \u201cExplore the Healthcare Map: The Most Complete View of the Patient Journey \u201d(2025) https:\/\/www.komodohealth.com\/solutions\/healthcare\u2010map\/."},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.029190"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.022376"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.12.048"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/03610910902859574"},{"issue":"3","key":"e_1_2_10_22_1","first-page":"141","article-title":"An Empirical Transition Matrix for Non\u2010Homogeneous Markov Chains Based on Censored Observations","volume":"5","author":"Aalen O. O.","year":"1978","journal-title":"Scandinavian Journal of Statistics"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1214\/aos\/1176344198"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.7326\/M16\u20102607"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2023.09.014"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12874\u2010019\u20100754\u20104"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11739\u2010011\u20100689\u20101"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.059595"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01375-3"},{"key":"e_1_2_10_30_1","volume-title":"Prevalence of Overweight, Obesity, and Severe Obesity Among Adults Aged 20 and Over: United States, 1960\u20131962 Through 2017\u20132018","author":"Fryar C. D.","year":"2020"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14593"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.70686","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/full-xml\/10.1111\/dom.70686","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.70686","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T03:10:02Z","timestamp":1780456202000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.70686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1111\/dom.70686"],"URL":"https:\/\/doi.org\/10.1111\/dom.70686","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.70686\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70686\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70686\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70686\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70686\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70686\/v1\/decision1","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"2025-12-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}